3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma, Synovial
2
Liposarcoma, Myxoid
2
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Graft vs Host Disease
1
Interventions
Temozolomide
58
Radiotherapy
50
Carmustine
23
Carboplatin
18
Filgrastim
17
Chemotherapy, Adjuvant
17
Irinotecan
12
Surgical Procedures, Operative
11
Peripheral Blood Stem Cell Transplantation
11
O(6)-benzylguanine
10
Magnetic Resonance Spectroscopy
10
Drug Therapy
10
Etoposide
9
sargramostim
8
Thiotepa
8
Thalidomide
8
Cyclophosphamide
8
Bevacizumab
8
Procarbazine
7
Gene Expression Profiling
7
Erlotinib Hydrochloride
7
Radiation
6
Everolimus
6
Cisplatin
6
motexafin gadolinium
5
aldesleukin
5
Topotecan
5
Imatinib Mesylate
5
Celecoxib
5
Busulfan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
Interferon-gamma
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled